Amended Annual Report (10-k/a)
June 10 2021 - 4:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K/A
(Amendment
No. 1)
[X]
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For
the fiscal year ended December 31, 2020
OR
[ ]
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For
the transition period from: _____________to______________
001-39199
(Commission
File Number)
TRxADE
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
46-3673928
|
(State
or Other Jurisdiction
of
Incorporation or Organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
3840
Land O’ Lakes Boulevard
Land
O’ Lakes, Florida 34639
(Address
of Principal Executive Office) (Zip Code)
(800)
261-0281
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.00001 Par Value Per Share
|
|
MEDS
|
|
The
NASDAQ Stock Market LLC
(Nasdaq
Capital Market)
|
Securities
registered pursuant to Section 12(g) of the Act:
None.
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No
[X]
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ]
No [X]
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes [X] No [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”
and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer [ ]
|
Accelerated
filer [ ]
|
Non-accelerated
filer [X]
|
Smaller
reporting company [X]
|
Emerging
growth [X]
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. [ ]
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
The
aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of the last business day
of the registrant’s most recently completed second fiscal quarter was approximately $21,541,008. For purposes of calculating the
aggregate market value of shares held by non-affiliates, we have assumed that all outstanding shares are held by non-affiliates, except
for shares held by each of our executive officers, directors and 5% or greater stockholders. In the case of 5% or greater stockholders,
we have not deemed such stockholders to be affiliates unless there are facts and circumstances which would indicate that such stockholders
exercise any control over our company, or unless they hold 10% or more of our outstanding common stock. These assumptions should not
be deemed to constitute an admission that all executive officers, directors and 5% or greater stockholders are, in fact, affiliates of
our company, or that there are no other persons who may be deemed to be affiliates of our company. Further information concerning shareholdings
of our officers, directors and principal stockholders is included or incorporated by reference in Part III, Item 12 of this Annual Report
on Form 10-K.
As
of March 26, 2021, there were 8,093,199 shares of common stock issued and outstanding.
DOCUMENTS
INCORPORATED BY REFERENCE
Portions
of the registrant’s definitive proxy statement relating to its 2021 annual meeting of stockholders (the “2021 Proxy Statement”)
are incorporated by reference into Part III of this Annual Report on Form 10-K.
EXPLANATORY
NOTE
TRxADE
HEALTH, INC. (formerly Trxade Group, Inc.)(the “Company”, “we” and “us”) is
filing this Amendment No. 1 (“Amendment No. 1”) to our Annual Report on Form 10-K for the year ended December 31,
2020 (the “Original Form 10-K”), as filed with the Securities and Exchange Commission on March 29, 2021 (the “Original
Filing Date”), solely to correct a typographical error in the Consent of Independent Registered Public Accounting Firm included
as Exhibit 23.1 thereto (the “Consent”) that resulted in an improperly worded auditor’s consent. A new
Exhibit 23.1 with the appropriate corrections is filed as Exhibit 23.1 attached hereto.
Except
as described above, no changes have been made to the Original Form 10-K and this Amendment No. 1 does not modify, amend or update in
any way any of the financial or other information contained in the Original Form 10-K. This Amendment No. 1 does not reflect events that
may have occurred subsequent to the Original Filing Date. This Amendment No. 1 is an exhibit-only filing. Except for Exhibit 23.1,
this Amendment does not otherwise update any exhibits as originally filed or previously amended.
Pursuant
to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also contains a new certification for our
Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 attached hereto.
Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure
with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 have been omitted from such certification. The Company is
not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial
statements are being filed with this Amendment No. 1.
PART
IV
Item
15. Exhibits, Financial Statement Schedules.
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
TRxADE
HEALTH, INC.
|
|
|
Date:
June 10, 2021
|
/s/
Suren Ajjarapu
|
|
By:
|
Suren
Ajjarapu, Chief Executive Officer (Principal Executive Officer)
|
TRxADE HEALTH (NASDAQ:MEDS)
Historical Stock Chart
From Mar 2024 to Apr 2024
TRxADE HEALTH (NASDAQ:MEDS)
Historical Stock Chart
From Apr 2023 to Apr 2024